Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Table 1 First line trials with molecular targeted therapies in advanced hepatocellular cancer

Trial	Drugs	Design	n	Median survival	HR	P value	Ref.
ASIA-PACIFIC	Sorafenib vs placebo	Superiority	150	6.5	0.68	0.01	[14]
			76	4.2
SHARP	Sorafenib vs placebo	Superiority	229	10.7	0.69	0.001	[2]
			303	7.9
SUNITINIB	Sunitinib vs sorafenib	Superiority	530	7.9	1.3	0.001	[22]
			544	10.2
BRISK-FL	Brivanib vs sorafenib	Non-inferiority	577	9.5	1.06	0.31	[28]
			578	9.9
LIGHT	Linifanib vs sorafenib	Non-inferiority	514	9.1	1.04	0.52	[24]
			521	9.8
SEARCH	Sorafenib/erlotinib vs sorafenib/placebo	Superiority	362	9.5	0.92	0.48	[29]
			358	8.5